Fate Therapeutics Inc (NASDAQ:FATE) currently has a daily average trading volume of 2.74M but it saw 1026808 shares traded in last market. With a market cap of 189.06M USD, the company’s current market price of $1.66 remained unchanged while comparing to the previous closing price of $1.66. In past 52 weeks, the stock remained buoying in the range of price level as high as $8.83 and as low as $1.57. In the recent trading on the day, stock has struck highest price mark of $1.615 while lowest mark touched by it was $1.675.
Taking a look at 20-day trading activity of Fate Therapeutics Inc (FATE) gives us an average price of $2.2678, while its current price level is -81.20% below from 52-week high level whereas it is 5.73% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.4727 while that of 200 days or SMA-200 reads an average of $3.8675. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.10% during that period while stretching the period over a month that increases to 13.27%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 35.31 which implies that the stock is in neutral territory.
Piper Sandler upgraded its recommendation for the stock as a “Overweight” from “Neutral” on June 17, 2024 while assigning a price target range of $4-$6. Wells Fargo issued its recommendations for the stock as it resumed the price target for the stock is $6.
Over the week, FATE’s stock price is moving -11.70% down while it is -27.51% when we observe its performance for the past one month. Year-to-date it is -55.61% down and over the past year, the stock is showing a downside performance of -51.46%.
Currently, Fate Therapeutics Inc’s total number of outstanding shares is 113.88M. Company’s return on investment (ROI) stands at -39.22% and return on equity (ROE) at -46.59%. Stock’s beta reads 1.98. Stock has a price to book (P/B) ratio of 0.52 while price to sale or P/S ratio amounts to 14.06. Its return on asset (ROA) is -34.32% on average.
